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AbstrAct
Introduction Statins are effective at preventing 
cardiovascular disease, widely prescribed and their use 
is growing. Uncertainty persists about whether they 
cause symptomatic muscle adverse effects, such as 
pain and weakness, in the absence of statin myopathy. 
Discrepancies between data from observational studies, 
which suggest statins are associated with excess muscle 
symptoms, and from randomised trials, which suggest no 
such excess, have caused confusion. N-of-1 trials offer the 
opportunity to establish whether muscle symptoms during 
statin use are caused by statins in particular individuals.
Methods and analysis This series of 200 randomised, 
double-blinded N-of-1 trials in primary care will determine 
(1) the effect of statins on all muscle symptoms and (2) 
the effect of statins on muscle pain that is perceived to be 
statin related. Patients who are considering discontinuing 
statin use due to muscle symptoms and those who have 
discontinued in the last 3 years due to such symptoms 
will be recruited. Participants will be randomised to a 
sequence of six 2-month treatment periods during which 
they will receive atorvastatin 20 mg per day or matched 
placebo. On each of the last 7 days of each treatment 
period, participants will rate their muscle symptoms on 
a Visual Analogue Scale (VAS). At the end of their trial, 
participants will be shown numerical and graphical 
summaries of their own symptom data during statin and 
placebo periods. The primary analysis on the aggregate 
data from all participants will be a linear mixed model for 
VAS muscle symptom score, comparing scores during 
treatment with statin and placebo.
Ethics and dissemination This trial received a favourable 
opinion from South Central-Hampshire A Research Ethics 
Committee. Results will be published in a peer-reviewed 
medical journal. Dissemination of results to patients will 
take place via the media, website ( statinwise. lshtm. ac. uk) 
and patient organisations.
trial registration number ISRCTN30952488.
IntroductIon
Statins reduce cardiovascular disease (CVD) 
risk1 and are widely recommended as part 
of the strategy for primary and secondary 
prevention of CVD.2–4 Although statins are 
widely prescribed,5 there is uncertainty about 
adverse effects.6 7 Severe adverse effects (rhab-
domyolysis, myopathy, diabetes mellitus and 
haemorrhagic stroke) are rare8 9; however, 
there has been widespread reporting in the 
lay and scientific media of other less well-de-
fined statin-related symptoms, particularly 
muscle pain in the absence of myopathy 
(ie, symptoms with raised creatine kinase 
(CK) blood levels). These reports have been 
prompted by data from non-randomised, 
non-blinded observational studies,10–12 but 
randomised controlled trials (RCTs) have 
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Protocol
strengths and limitations of this study
 ► This trial will determine whether statins cause 
muscle symptoms during statin use in these 
participants, allowing clinician and participant to 
make an informed decision about continued use.
 ► This trial will evaluate a novel pathway of care for 
general  practitioners to determine the cause of 
muscle symptoms during statin use.
 ► Patients who have previously experienced intolerable 
muscle pain during statin use may be unwilling to 
participate in the trial, therefore results cannot be 
generalised to them.
 ► The study will only assess the effects of a single 
statin at a single dose.
 ► The study will only capture symptoms arising within 
the 2-month treatment period.
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found no evidence of an effect on these symptoms.13 A 
recent review of the evidence from randomised trials 
and observational studies suggested that symptomatic 
adverse events may be misattributed to statins,9 and 
there is further evidence from trials of statins of this 
misattribution.14 
Uncertainty about the association between muscle 
symptoms and statins persists due to limitations of obser-
vational studies and trials. A major limitation of obser-
vational studies is a lack of blinding; patients taking a 
medication expect to experience adverse effects,15 and 
therefore reporting of symptoms in statin users may be 
higher than in a comparable population not on statins. 
This phenomenon, the ‘nocebo’ effect, can lead to bias 
in unblinded studies.
In trials, outcome definitions have been inconsistent,6 
and the temporal nature of muscle symptoms related to 
statins may not be compatible with the nature of adverse 
event collection. Another important consideration is dilu-
tion bias; even in the absence of statins, musculoskeletal 
symptoms are very common among the age groups of 
people most likely to take statins and could dilute any true 
effect of statins on muscle pain. In the randomised Heart 
Protection Study, around one-third of participants in the 
placebo arm reported unexplained muscle pain or weak-
ness in response to regular direct questioning from the 
study nurse, with an almost identical proportion among 
participants in the statin arm.16 Dilution of statin-related 
symptoms by non-statin-related symptoms would have 
led to a bias towards the null.17 Overcoming this bias 
and disentangling statin-related from non-statin-related 
muscle symptoms is key in determining whether statins 
cause muscle symptoms.
Despite evidence-based recommendations about the 
risks and benefits of statin use, many patients believe 
that their muscle symptoms are due to statins and discon-
tinue use, therefore potentially missing out on the poten-
tial benefits. Clinicians faced with patients presenting 
with muscle symptoms during statin use are encouraged 
to measure the blood CK, which is substantially elevated 
in the rare cases of statin-associated myopathy, but in the 
vast majority of patients, the CK level will be normal, ruling 
out myopathy. In these cases, there is currently no other 
diagnostic tool allowing clinicians to empirically evaluate 
whether symptoms reported by an individual statin user 
are caused by the statin itself or by the ‘nocebo’ effect.
Therefore, this series of N-of-1 trials aims to offer the 
opportunity for individual patients to discover whether 
the symptoms that they are experiencing are attribut-
able to statins. Each patient acts as their own control, 
and the treatment that minimises their symptoms can be 
established.18 19 The proposed trial will address some of 
the criticisms of previous evidence. The trial is double-
blinded and placebo-controlled to minimise bias, and the 
sequence of statin and placebo treatments is randomised. 
Additionally, the within-patient comparisons of symp-
toms experienced while on placebo and statin will allow 
us to determine (1) the effect of statins on all muscle 
symptoms and (2) the effect of statins on muscle pain that 
is perceived to be statin related.
MEthods
study design
A series of randomised, double-blind, placebo-controlled 
N-of-118 19 trials in primary care.
Each participant in the study can be seen as having 
their own RCT, and StatinWISE is a series of 200 of these, 
which is equivalent to a single multiple-crossover study of 
200 patients.
N-of-1 trials can be demanding on the time of both 
patient and clinician, and StatinWISE has been designed 
with both of these groups in mind. As described in the 
methods that follow, general practitioners (GPs) are 
asked to perform as few trial-related tasks as possible 
and are asked to follow standard care in the follow-up of 
participants. Trial visits and procedures for participants 
themselves are minimised, and outcomes are collected 
using a choice of methods.
study population
This study is taking place in primary care across England 
and Wales. Participating GP practices will recruit eligible 
patients from two groups as follows:
1. patients who are considering discontinuation of their 
statin due to muscle symptoms,
2. patients who have stopped taking statin in the last 
3 years due to muscle symptoms.
Inclusion criteria
 ► Adults (aged 16 years and above).
 ► Registered in a participating GP practice.
 ► Previously prescribed statin treatment in the last 3 
years.
 ► Stopped or is considering stopping statin treatment 
due to muscle symptoms.
 ► Provided fully informed consent.
Exclusion criteria
 ► Patient has any previously documented serum alanine 
aminotransferase (ALT) levels at or above three times 
the upper limit of normal.
 ► Patient has persistent, generalised, unexplained 
muscle pain (whether associated or not with statin 
use) and blood CK levels greater than five times the 
upper limit of normal.
 ► Patient has any contraindications listed in the 
Summary of Product Characteristics (SmPC) for ator-
vastatin 20 mg, including pregnancy.
 ► Patient should not participate in the trial in the 
opinion of the GP.
Patients who have not had a CK and ALT test within the 
previous 3 months will be required to undergo these tests 
prior to randomisation to ensure eligibility.
recruitment
Participants will be recruited directly from GP Practices 
or by advertising to the public.
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Table 1 Treatment sequences in StatinWISE (S=statin and 
p=placebo)
Treatment period
1 2 3 4 5 6
Sequence 1 S P S P S P
Sequence 2 S P S P P S
Sequence 3 S P P S S P
Sequence 4 S P P S P S
Sequence 5 P S S P S P
Sequence 6 P S S P P S
Sequence 7 P S P S S P
Sequence 8 P S P S P S
(1)Patients who are considering discontinuation of their 
statin due to muscle symptoms: These patients will be invited 
to take part in the trial when they visit the GP to report 
muscle symptoms believed to be associated with statins, 
and where the patient/GP is considering stopping statins 
because of the muscle symptoms. The GP or research 
nurse will approach the patient with an invitation to take 
part in the trial.
(2)Patients who have stopped taking statin in the last 3 years 
due to muscle symptoms: A search of the practice electronic 
records will be performed on a two monthly basis for 
1 year (or until recruitment targets are reached) to iden-
tify potentially eligible patients. The list will be reviewed 
by the GP to confirm clinical eligibility before patients are 
invited to take part.
A letter inviting them to attend a screening visit, 
accompanied with the patient information sheet 
(online supplementary appendix 1) for the patient to 
consider, will be sent by the trial team from their GP 
practice.
(3) Patients who contact the CTU from advertising: Patients 
who contact the CTU in response to advertising mate-
rial will be sent a letter to request their GP details on a 
reply slip. Following receipt of these documents the CTU 
will contact their GP with their consent. The GP will be 
asked to confirm that the patient is potentially suitable 
for the trial and to provide brief clinical information to 
allow eligibility to be assessed. This information will then 
be provided to the GP surgery responsible for recruiting 
the patient.
Patients will have the opportunity to ask the research 
nurse any questions during the screening visit. The nurse 
will ensure that the patient understands the study and will 
record their informed consent (online supplementary 
appendix 2).
Assignment of interventions
Consenting patients eligible for inclusion will be 
randomised by the research nurse/GP practice trial team 
using the online London School of Hygiene and Trop-
ical Medicine (LSHTM) clinical trials unit (CTU) rando-
misation system, which will allocate them to a sequence 
of blinded placebo and atorvastatin treatment periods. 
There are six treatment periods each of 2 months’ dura-
tion (each treatment period is exactly 8 weeks in dura-
tion). Each individual will be randomised to three paired 
blocks of treatment (either statin then placebo or placebo 
then statin), which is equivalent to randomisation, with 
equal probability, to one of the eight sequences shown 
in table 1 (with p=placebo and S=statin). There is no 
washout period at study initiation.
Randomisation codes will be generated and secured by 
the Information Technology team at LSHTM CTU, which 
has procedures to ensure that the trial team remains 
blinded. The codes will be made available to a Good 
Manufacturing Practice (GMP) certified clinical trial 
supply company explicitly for the treatment packs to be 
created in accordance with the randomisation list.
blinding
The participant, general practice staff and trial team 
will all be blind to the participant’s sequence allocation. 
Placebo will be manufactured specially to match the 
atorvastatin by a GMP certified manufacturer. Capsules 
and packaging will be identical in appearance for both 
active treatment and placebo. Participants will be asked to 
swallow the capsule whole without chewing or breaking it 
to minimise the risk of unblinding. The blinding process 
and first stage Qualified Person release will be done by 
the designated clinical trial supply company.
Unblinding will be available if a clinician believes that 
clinical management depends importantly on knowledge 
of whether the patient is currently receiving statin or 
placebo. In these cases, a 24-hour telephone service will 
be provided with the unblinding notified directly to the 
clinical requesting it.
Interventions
The trial treatment consists of once per day oral admin-
istration of atorvastatin (20 mg) capsules or a matching 
placebo capsule (microcrystalline cellulose). The treat-
ment phase will be 1 year for each participant. Partic-
ipants will receive a 2-month (8 weeks) supply of trial 
treatment by post, through six treatment periods, and 
asked to take one capsule per day, swallowed whole. Two 
months is sufficient time for symptoms to appear in most 
patients20 21 and to washout from the previous treatment 
period (median time to symptom improvement was 2 
weeks following cessation).22
Modifications to the trial treatment
For participants who experience intolerable muscle 
symptoms, the GP will be asked to follow standard care 
guidelines and measure the participant’s CK and alanine 
transaminase. If the CK and ALT are within the normal 
range and the participant remains eligible, they can be 
offered the following options by the GP:
1. Continue with their current trial treatment.
2. Reduce the frequency to every other day.
3. Stop for that treatment period and resume at the start 
of the next period.
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box secondary outcomes
1. Whether or not participants with muscle symptoms during each 
2-month period believe that their symptoms were caused by the 
study medication, comparing periods of statin treatment with 
placebo.
2. Site of muscle symptoms (single or multiple; head and neck/upper 
limbs/lower limbs/trunk).
3. Among participants reporting muscle symptoms, the Visual 
Analogue Scale scores (range 0–10) for the following, comparing 
periods of statin treatment with placebo:
a. General activity
b. Mood
c. Walking ability
d. Normal work (includes both work outside the home and 
housework)
e. Relations with other people
f. Sleep
g. Enjoyment of life
8. Other symptoms that the participant believes can be attributed to 
the study medication (grouped: musculoskeletal, gastrointestinal, 
respiratory, neurological, psychological and other).
9. Adherence to study medication as assessed by: (1) self-report 
and (2) counting pills remaining in returned packages, and the 
relationship between adherence and muscle symptoms.
10. Participant decision regarding future statin use and the relationship 
to their primary outcome.
11. Whether participants found their own trial result helpful in making 
the decision about future statin use.
A participant is free to change their mind about partic-
ipation at any time and would be advised to see their GP 
to discuss future routine care. A GP can withdraw a partic-
ipant at any time if concerns arise or if the participant 
presents with any reason to stop atorvastatin as described 
in the SmPC for atorvastatin 20 mg.
Monitoring adherence to the trial treatment
Adherence to trial treatment will be assessed by: (1) 
self-reporting, as part of outcome data collection and 
(2) counting pills remaining in returned packages 
(participants will be asked to return any empty or unused 
pill packets using stamped addressed envelopes provided 
with their treatment packs).
concomitant care
Throughout the trial, continued participant care will be at 
the discretion of their GP. In primary care, the participant 
will be recorded as having an ongoing statin prescription.
 ► Where treatment with an interacting drug is needed 
that will be for less than 1 month duration, the partic-
ipant will be asked to stop the trial treatment for that 
period.
 ► Where treatment with an interacting drug is needed 
for longer than 1 month, the participant will be asked 
to withdraw from trial treatment completely.
Participants will be provided with an alert card that 
identifies them as a being randomised in StatinWISE. 
Participants will be asked to present this card to anyone 
providing medical care outside of their usual GP practice. 
The card will have a link to the trial website and their GP 
practice contact number.
optional genetic study
Participants will also be invited to contribute to a larger 
study that aims to identify genetic variants associated 
with adverse effects of statins, for which 9 mL of blood 
is required. Participation is optional and will not affect 
involvement in the main trial.
outcoMEs
Primary outcome
The primary outcome is self-reported ‘muscle symptoms’, 
defined as pain, weakness, tenderness, stiffness or cramp 
to the body of any intensity; these are the symptoms most 
commonly reported by patients and are often the reasons 
for discontinuation. Though this primary outcome has 
a broad definition, making it potentially vulnerable to 
dilution bias (17 and as discussed above), it has the key 
advantage of allowing participants to report any muscle 
symptoms, without constraining them to report only 
those that they are confident are statin related. Measures 
to deal with dilution bias are discussed in the Secondary 
analyses section.
The primary outcome will be assessed by the mean 
difference in Visual Analogue Scale (VAS) scores between 
treatment periods with atorvastatin and treatment periods 
with placebo, estimated via a linear mixed model.
In the seventh week of each 2-month treatment period, 
participants will receive reminders to alert them that 
follow-up data collection is approaching. Symptom scores 
on the VAS will be collected daily in the eighth week 
of each treatment period. Participants can choose to 
receive daily reminders on each day their data is due to 
be collected. Non-responders will automatically receive a 
reminder from the trial team after 24 hours of the due 
date.
secondary outcomes
Secondary outcomes (box) relate to participant belief 
about the cause of their muscle symptoms, the site of 
muscle symptoms, how the muscle symptoms affect the 
participant and information about any other symptoms.
A key secondary outcome is pain for which the partici-
pant answers ‘yes’ or ‘don’t know’ to the question ‘Do you 
think these muscle symptoms are related to your study 
medication?‘, asked at the end of each treatment period. 
People answering ‘no’ to this question would have their 
VAS scores set to zero for that treatment period for this 
specific secondary outcome.
Secondary outcome number three in box were taken 
from the Brief Pain Inventory.23 Other secondary 
outcomes are adherence to medication, the partici-
pant’s decision about statin treatment following the trial 
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Figure 1 Trial overview.
and whether they found their own trial result helpful in 
reaching that decision.
data collection methods
Baseline
Baseline data will include demographic information, 
contact details, an eligibility assessment and general 
medical history. These data will be collected at each GP 
practice by the GP or research nurse and will be entered 
directly into the online bespoke trial database provided 
by the LSHTM CTU.
Participants will choose the method of data collection 
most suitable for them, from the following:
1. Bespoke mobile app, which will require participants 
to use their own smartphone.
2. Online database using a computer, phone or tablet.
3. Paper forms which they will receive by post at the 
same time as their trial treatment and which they can 
complete themselves or they can request a trial team 
member to contact them by phone to help with com-
pleting the forms.
4. Trial staff will telephone the participant on each data 
collection day and complete the questionnaire based 
on the participant answers.
Treatment phase follow-up
Follow-up symptoms and adherence data will be collected 
directly from each participant using their preferred data 
collection method. Reminders will be sent to participants, 
as described above, to encourage complete submission of 
data.
End of trial data
Participants, together with their GP, will receive their 
individual results within two  months of the last treatment 
period and will discuss these with the GP or research 
nurse. Three months after the last treatment period 
(month 15), trial staff will email/telephone the partici-
pant to document their decision on future statin use and 
whether their results helped reach this decision.
Participant timeline
See figure 1 and online supplementary appendix 3.
sample size calculation
The power calculations are based on being able to detect a 
1 cm difference in the VAS pain score. This was chosen to 
represent the smallest VAS change in pain which patients 
would perceive as being beneficial and might therefore 
change a patient’s decision regarding subsequent statin 
use. Two studies have concluded that the smallest change 
in VAS pain score corresponding to ‘a little more’ or ‘a 
little less’ pain was 1.3 cm, with a lower limit of the CI 
at 1 cm.24 25 A 1.3 cm minimum change value was used 
to power a pilot series of N-of-1 trials for statin adverse 
effects,26 and our study is therefore powered for a 1 cm 
change as a conservative estimate of the smallest benefi-
cial change.
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Using simulation, we estimated that a sample size of 64 
participants provides approximately 90% power to detect 
a treatment effect of at least 1 cm, assuming a type I error 
of 5%. Allowing for loss to follow-up of 40% of partici-
pants through the trial inflates the required sample size 
to 107 participants.
Period effects (changes in underlying VAS pain score 
due to factors other than randomised treatment, for 
example, seasonal and activity-related), variability in indi-
vidual statin effects across participants and imperfect 
adherence to the assigned treatment were investigated 
by further detailed simulations. VAS pain scores are not 
normally distributed, since they are bounded (0–10 cm) 
and can display large fluctuations in response. Therefore, 
further power calculations were performed drawing the 
outcome from a Beta distribution and from a distribu-
tion with normal variance components on a logit scale, 
to assess the robustness of the sample size estimates to 
the distribution chosen. These factors all have the effect 
of decreasing power, thus increasing the sample size 
required. An approximately 80% increase in the sample 
size required in the absence of these effects provided 
approximately 90% or more power across a plausible 
range of these potential effects, thus we determined that 
a final sample size of 200 was required.
statistical methods
Primary analysis
To estimate the population average estimate of the trial 
VAS muscle symptom score, data from each N-of-1 trial 
will be aggregated. We will adopt an intention-to-treat 
approach. Participants who enter data on muscle symp-
toms at least once during a treatment period with statin 
and at least once during a treatment period with placebo 
will be included in the primary analysis.
The primary analysis will be a linear mixed model 
for VAS muscle symptom score with random effects for 
participant and allowing the treatment effect to vary 
randomly across participants. Residual errors will be 
modelled using a first-order autoregressive error struc-
ture within each treatment period to account for correla-
tion between the seven daily measurements, with robust 
standard errors to account for non-normality of the VAS 
scores. Although VAS muscle symptom scores are unlikely 
to be exactly normally distributed, analysing such data 
using normal-based methods is likely to be a sufficiently 
robust approach.27 Sensitivity analyses will explore the 
robustness of conclusions to period effects, within-par-
ticipant correlation structures and missing data. All tests 
will be two-sided. P<0.05 will be considered statistically 
significant.
Secondary analyses
The secondary outcomes include a single binary measure 
of whether the participant reports having muscle symp-
toms during that treatment period or not. This will also 
be combined with the follow-up question pertaining to 
attribution, to obtain a single binary measure of whether 
the participant reports having muscle symptoms that they 
attribute to the trial treatment or not. These two binary 
outcome measures will be assessed using a logistic mixed 
model with random participant and treatment effects and 
fixed period effects.
We will also perform a secondary analysis using the daily 
VAS scores, in combination with the follow-up question 
pertaining to attribution. This analysis will be performed 
in the same way as the primary analysis, but with VAS 
scores set to zero if the patient attributes their symptoms 
to a non-statin-related cause.
By removing symptoms with a known cause, these 
secondary analyses will be restricted to symptoms that the 
participant believes could be due to their study medica-
tion. This could reduce possible dilution bias that may be 
present in the primary outcome. If the secondary anal-
yses of muscle symptoms that the participant attributes 
to the study medication produce a substantially higher 
measure of effect than the primary analysis of all muscle 
symptoms, then this suggests that the primary result may 
have been affected by dilution bias.
Secondary outcomes relating to the impact of the ator-
vastatin treatment on other aspects of life will be analysed 
in a similar manner to the primary outcome, omitting the 
autoregressive correlation structure since these secondary 
outcomes are measured once per treatment period.
We will investigate whether the excess muscle symp-
toms, if any, experienced during treatment periods with 
statin are at a single body site versus multiple sites, and 
whether symptoms are more common at any specific 
body site.
Descriptive statistics will be used to summarise the 
measures of adherence to randomised treatment and 
their relationship to the statin and placebo periods. We 
will use the measures of adherence to randomised treat-
ment to perform an efficacy analysis based around an 
instrumental variables approach.28 Since these analyses 
require much stronger assumptions than the intention-
to-treat analysis above, the results of the efficacy analysis 
will be presented and interpreted as a secondary analysis.
We will relate the participant’s decision regarding future 
statin use, and whether or not the participant found their 
own result helpful in making their subsequent treatment 
decisions, to their individual estimated effect of the ator-
vastatin treatment.
Subgroup analyses
There are no a priori subgroup analyses planned. If an 
overall population-level effect is detected, we may inves-
tigate whether the effect varies within subgroups defined 
by measured baseline characteristics. These analyses will 
be presented and interpreted as being exploratory.
data monitoring
An independent data monitoring committee (DMC) has 
been appointed for this trial to oversee the safety moni-
toring. The DMC will review accumulating data on a 
regular basis from the ongoing trial and advise the trial 
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steering committee (TSC) regarding the continuing 
safety of current participants and those yet to be recruited, 
as well as reviewing the validity and scientific merit of the 
trial. An independent statistician is appointed to provide 
the analysis service required by the DMC.
The intervention (atorvastatin) has a marketing authori-
sation in the UK and has been in clinical use for decades. 
Atorvastatin is not a new drug and has a well-documented 
safety profile. Furthermore, this trial is being conducted 
in a population in which statin use is clinically indicated. 
It is anticipated that participants in this trial are at higher 
risk of CVDs because of underlying clinical conditions 
requiring statin use. Additionally, as participation is for 
15 months, it is likely that they will have common medical 
problems (eg, colds, coughs and fevers). On the basis 
that: (1) participants would have had prior exposure 
to the trial treatment, (2) the trial treatment is clinically 
indicated for their medical condition and (3) the known 
safety profile of the trial treatment, we will limit adverse 
events reporting to any untoward medical occurrence not 
listed in the Investigational Medicinal Product Dossier 
and/or SmPC affecting a trial participant which at any 
dose:
 ► results in death
 ► is life-threatening
 ► requires inpatient hospitalisation or prolongation of 
existing hospitalisation
 ► results in persistent or significant disability/incapacity
 ► is a congenital anomaly/birth defect.
These events will be reviewed routinely by the trial 
Medical Advisor and will be reported routinely to the 
DMC. There are no extra tests or procedures unless 
participants agree to contribute a DNA sample to the 
optional genetic study, for which a 9 mL blood sample is 
required.
We will use central monitoring29 along with investiga-
tors’ training and meetings and extensive written guid-
ance to make sure the trial is carried out properly. We 
plan to carry out onsite monitoring where central statis-
tical monitoring shows abnormality. Consent forms will 
be monitored centrally at the CTU.
Investigators/GP practices are required to provide 
direct access to source data/documents for trial-related 
monitoring, audits, ethics committee review and regu-
latory inspection. The majority of source data will be 
electronic from the web database and mobile app. All 
trial-related and source documents must be kept for 5 
years after the end of the trial.
harms
Known serious adverse effects of statins (rhabdomy-
olysis and myopathy) are extremely rare. Patients who 
have previously experienced rhabdomyolysis or myop-
athy will be excluded from the trial, based on informa-
tion provided from each participant’s GP. This trial aims 
to address uncertainty about less severe side effects of 
statins, but participants experiencing intolerable symp-
toms should report these to their GP and a decision 
about whether to continue with the study can then be 
made.
Auditing
The study may be subject to audit by the LSHTM under 
their remit as sponsor and other regulatory bodies to 
ensure adherence to GCP.
Patient and public involvement
Three patient representatives are on the TSC, and a Stat-
inWISE patient involvement group has provided feedback 
on the trial design, patient information sheet and data 
collection tools. The group will continue to be involved 
through the course of the trial and will play an important 
role in designing materials for dissemination.
EthIcs And dIssEMInAtIon
Ethical issues
Approvals
Protocol amendments will be submitted for approval to 
the ethics committee, will be updated on trial registries 
and will be circulated to all study sites.
Informed consent
Informed consent will be obtained by the GP or research 
nurse (online supplementary appendix 2). Informed 
consent will also be requested for a blood sample for an 
optional genetic study and for that blood sample to be 
retained for use in future ethically approved studies.
Confidentiality
Participant data will be accessed only by authorised 
personnel from the LSHTM. All will have a duty of 
confidentiality, and no data will be disclosed outside the 
research site. All participant and GP practice-level infor-
mation will be confidential.
Post-trial care
The follow-up period ends 15 months after the first treat-
ment day with a final contact (telephone or face-to-face) 
with the research nurse. This will be considered as the 
end of trial for participants, and further routine clinical 
care will be provided by their GP.
dissemination plans
The trial results will be published in peer-reviewed 
journals. All publications will follow the Consolidated 
Standards of Reporting Trials statement.30 Links to the 
publication will be provided in all applicable trial regis-
ters. Dissemination of results to patients will take place via 
the media, trial website ( statinwise. lshtm. ac. uk) and rele-
vant patient organisations. The results of the trial will be 
reported first to trial collaborators. Collaborating investi-
gators will play a vital role in disseminating the results to 
colleagues and patients. Authorship for all publications 
will be based on the criteria defined by the International 
Committee of Medical Journal Editors.31
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